Key result
A case of pulmonary tumor thrombotic microangiopathy was associated with a presumed lung adenocarcinoma primary, highlighting it as a differential diagnosis for chronic dyspnea of unknown origin.
Case Report (n=1)
PTTM should be considered in the differential diagnosis for patients presenting with chronic dyspnea of unknown origin, severe pulmonary hypertension, and right-sided heart failure without pulmonary embolism.
May support PTTM consideration in unexplained chronic dyspnea with pulmonary hypertension; case report leaves open prospective validation.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare rapidly progressive fatal disease that is difficult to diagnosis antemortem. Activation of the coagulation cascade and fibrocellular intimal thickening caused by embolism of tumor cells into pulmonary vasculature leads to extensive pulmonary hypertension and eventually death. We describe a case of PTTM with association of a presumed lung adenocarcinoma primary. Although rare in nature, PTTM should be a considered diagnosis with chronic dyspnea of unknown origin, severe pulmonary hypertension coupled with right-side heart failure, in the absence of pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Hutchinson et al. (2017) conducted a case report in Pulmonary tumor thrombotic microangiopathy (n=1). A case of pulmonary tumor thrombotic microangiopathy was associated with a presumed lung adenocarcinoma primary, highlighting it as a differential diagnosis for chronic dyspnea of unknown origin.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: